CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Medical Coverage Policy Molecular Testing for the Management of Pancreatic Cysts, Barrett Esophagus, and Solid Pancreaticobiliary Lesions

Defines medical necessity criteria, documentation, prior authorization, coverage stance, and billing guidance for PathFinderTG molecular/topographic genotyping (eg PancraGEN, BarreGEN) when used as a second-line diagnostic adjunct for pancreatic cyst fluid, Barrett esophagus, and solid pancreaticobiliary lesions for Medicare Advantage and Commercial products.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMedical Coverage Policy Molecular Testing for the Management of Pancreatic Cysts, Barrett Esophagus, and Solid Pancreaticobiliary Lesions

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 1, 2024

Next Review Date

Key ActionObtain prior authorization for Medicare Advantage (recommended for Commercial) via the payer's online tool and document in the medical record why first-line diagnostics were insufficient.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes identified in this update.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Overview: PathFinderTG is a topographic genotyping (molecular anatomic pathology) platform that integrates microscopic anatomic pathology microdissection with molecular analysis to increase tumor cell yield from small or minute specimens. It is positioned as an occasional second-line diagnostic adjunct when first-line analyses are inconclusive for pancreatic cysts, Barrett esophagus, or solid pancreaticobiliary lesions. Coverage stance is mixed: the policy defines specific medical necessity criteria for use in pancreatic cyst fluid evaluation (primary covered indication) while other indications are not covered. Regulatory status: PathFinderTG is offered as a laboratory-developed test (LDT) under CLIA; the U.S. Food and Drug Administration has not required regulatory review of this test.

Policy metadata

Effective date2024-01-01

Last review2023-09-20

StatusCURRENT

Primary covered indication count1 (Primary covered indication: pancreatic cyst fluid evaluation)

Scope summary highlightsDefines medical necessity criteria, documentation, prior authorization, coverage stance, and billing guidance for PathfinderTG as a second-line diagnostic adjunct for pancreatic cyst fluid, Barrett esophagus, and solid pancreaticobiliary lesions.

Threshold badgePancreatic cyst fluid carcinoembryonic antigen (CEA) >= 200 ng/mL

Medical Necessity Criteria

Medicare Advantage Plans and Commercial Products - Covered Indication (pancreatic cyst evaluation)

ALL of the following

A decision regarding treatment (e.g., surgery) has NOT already been made based on existing information.
There remains clinical uncertainty as to either current malignancy or the malignant potential of the pancreatic cyst after a comprehensive first-line evaluation.
Evidence of prior first-line diagnostics (ONE or more of the following)
- Pancreatic cyst fluid carcinoembryonic antigen (CEA) >= 200 ng/mL, suggesting a mucinous cyst but not diagnostic.>= 200 ng/mL

Not Covered Indications

Medicare Advantage Plans and Commercial Products - Not Covered Indications

All other PathfinderTG indications are not covered due to insufficient data on analytical and/or clinical validity.

ANY of the following

Any PathfinderTG use other than pancreatic cyst fluid evaluation (eg, uses for other indications beyond pancreatic cyst fluid) is considered not covered.

All other PathfinderTG indications are not covered due to insufficient data on analytical and/or clinical validity. Uses of PathfinderTG other than pancreatic cyst fluid evaluation (for example, for other diagnostic indications such as Barrett esophagus or solid pancreaticobiliary lesions) are considered not covered.

Coding

Suggested Reporting Codes (no established CPT/HCPCS code)CPT|HCPCS

84999	Unlisted chemistry procedure (suggested unlisted CPT code when no specific code exists)
81479	Unlisted molecular pathology procedure (suggested unlisted CPT code when no specific code exists)

Provider Actions & Billing Rules

Prior Authorization

Prior authorization required for Medicare Advantage

Prior authorization is required for Medicare Advantage Plans and recommended for Commercial Products and must be obtained via the payer's online tool for participating providers.

Documentation Required

Medical record documentation requirements

Maintain legible medical record pages with patient identification and provider signature; documentation must support the selected ICD-10-CM and CPT/HCPCS codes and the medical necessity per policy, including why first-line diagnostics were insufficient.

Legible medical record pages with patient identification and provider signature
Documentation that supports the selected ICD-10-CM and CPT/HCPCS code(s)
Documentation of medical necessity per policy (why PathfinderTG is needed)
Clear explanation of why and how first-line diagnostics were insufficient

Background & Definitions

Background: Topographic genotyping (PathFinderTG) combines microscopic identification and microdissection of areas of interest with molecular testing to increase tumor cell yield and may permit pathologic diagnosis when first-line analyses are inconclusive. The test is intended as an occasional second-line adjunct (for example, when cyst cytology, cyst fluid CEA, or imaging remain indeterminate and testing is expected to influence management). Regulatory oversight: PathFinderTG is performed as a laboratory-developed test under CLIA for high-complexity testing; to date the FDA has not required review. Documentation and prior authorization requirements apply when coverage criteria are used.

Definitions

Evidence & Regulatory Note

Medicare Determinations

LCD Name	LCD Number	Type	Effective Date	Note
Local Coverage Determination: Loss-of-Heterozygosity Based Topographic Genotyping with PathfinderTG		LCD		Details not provided in source for blank fields (number and effective date).

Revision History

2023-09-20last_review

Last review

2024-01-01effectiveLatest

Policy effective